We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Method Using DNA Nanoballs to Revolutionize Pathogen Detection

By LabMedica International staff writers
Posted on 08 Sep 2023
Image: Electronic detection of DNA nanoballs enables simple pathogen detection (Photo courtesy of 123RF)
Image: Electronic detection of DNA nanoballs enables simple pathogen detection (Photo courtesy of 123RF)

Throughout the recent COVID-19 pandemic, protein-based diagnostics played a significant role in rapid testing. However, developing high-quality antibodies for these methods is time-consuming. In contrast, nucleic acid-based approaches offer advantages in terms of development ease, sensitivity, and flexibility. Scientists have now pioneered a novel technique using DNA Nanoballs for pathogen detection that could simplify nucleic acid testing and revolutionize pathogen identification. Their research could pave the way for a simple electronic-based test to quickly and affordably identify various nucleic acids in diverse scenarios.

The methodology developed by researchers at Karolinska Institute (Stockholm, Sweden) combined Molecular Biology (specifically DNA Nanoball generation) with electronics (electric impedance-based quantification) to create this groundbreaking detection tool. They are cautiously optimistic about its potential to identify a range of pathogenic agents in real-world settings. The team modified an isothermal DNA amplification reaction called LAMP to produce tiny DNA nanoballs measuring 1-2μM if the pathogen was present in the sample. These nanoballs are then guided through tiny channels and electrically identified as they pass between two electrodes. The method has demonstrated impressive sensitivity, capable of detecting as few as 10 target molecules, and provides rapid results in under an hour using a compact, stationary system.

This label-free detection method has the potential to accelerate the development of new diagnostic kits. By combining affordable mass-produced electronics with lyophilized reagents, it could become a cost-effective, widely accessible, and scalable point-of-care device. Currently, the research team is actively exploring applications in fields such as environmental monitoring, food safety, virus detection, and antimicrobial resistance testing. They are also considering licensing options and establishing a startup to leverage this technology, having recently applied for a patent.

“Fast and accurate detection of genetic material is key for diagnosis, especially so in response to the emergence of novel pathogens,” said principal investigator Vicent Pelechano.

Related Links:
Karolinska Institute 

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter

Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more